AI assistant
TransMedics Group, Inc. — Director's Dealing 2025
Nov 26, 2025
31201_dirs_2025-11-26_0a579acb-f062-46a0-85e2-fbfaf0eb04e9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: TransMedics Group, Inc. (TMDX)
CIK: 0001756262
Period of Report: 2025-11-25
Reporting Person: Ranganath Anil P. (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-11-25 | Common Stock | M | 3000 | $93.88 | Acquired | 16955 | Direct |
| 2025-11-25 | Common Stock | S | 3000 | $145.22 | Disposed | 13955 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-11-25 | Stock Option (Right to Buy) | $93.88 | M | 3000 | Disposed | 2033-08-01 | Common Stock (3000) | Direct |
Footnotes
F1: The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $145.00 to $145.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F2: The option vested as to 25% on June 5, 2024 and will vest as to the remaining shares in equal monthly installments over three years thereafter, subject to continued service.